Duration of serological response to canine parvovirus-type 2, canine distemper virus, canine adenovirus type 1 and canine parainfluenza virus in client-owned dogs in Australia
Article first published online: 15 NOV 2012
© 2012 The Authors. Australian Veterinary Journal © 2012 Australian Veterinary Association
Australian Veterinary Journal
Volume 90, Issue 12, pages 468–473, December 2012
How to Cite
Mitchell, S., Zwijnenberg, R., Huang, J., Hodge, A. and Day, M. (2012), Duration of serological response to canine parvovirus-type 2, canine distemper virus, canine adenovirus type 1 and canine parainfluenza virus in client-owned dogs in Australia. Australian Veterinary Journal, 90: 468–473. doi: 10.1111/j.1751-0813.2012.01009.x
- Issue published online: 27 NOV 2012
- Article first published online: 15 NOV 2012
- Manuscript Accepted: 22 MAY 2012
- Pfizer Animal Health
- serological response;
To determine whether client-owned dogs in Australia, last vaccinated with Canvac® vaccines containing canine parvovirus-type 2 (CPV-2), canine distemper virus (CDV), canine adenovirus type 2 (CAV-2) ± canine parainfluenza virus (CPiV) at least 18 months ago, were seropositive or responded serologically to revaccination.
A total of 235 dogs were recruited from 23 veterinary clinics, representing a variety of breeds, ages and time since last vaccination (TSLV: range 1.5–9 years, mean 2.8 years). Dogs had a blood sample taken and were revaccinated on day 0. A second blood sample was taken 7–14 days later. Blood samples were assessed for antibody titres to CPV-2 (by haemagglutination inhibition) and CDV, CAV type 1 (CAV-1) and CPiV (by virus neutralisation). Dogs with a day 0 titre >10 or a four-fold increase in titre following revaccination were considered to be serological responders.
The overall percentage of dogs classified as serological responders was 98.7% for CPV-2, 96.6% for CDV, 99.6% for CAV-1 and 90.3% for CPiV.
These results suggest that the duration of serological response induced by modified-live vaccines against CPV-2, CDV, CAV-1 and CPiV, including Canvac® vaccines, is beyond 18 months and may extend up to 9 years. Accordingly, these vaccines may be considered for use in extended revaccination interval protocols as recommended by current canine vaccine guidelines.